Ozempic Gastroparesis Settlement: Criteria Explained

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health to Specific Risk

For years, general health and science information has served as a foundational resource for individuals seeking to understand broad wellness topics, from nutrition to chronic disease management. This legacy context provided a baseline of knowledge, helping people navigate the complex landscape of medical advice and treatment options. Within this framework, discussions around metabolic health and weight management have become increasingly prominent, particularly as new pharmaceutical interventions have entered the market. The conversation now shifts to a more specific area of concern: the use of glucagon-like peptide-1 receptor agonists, such as Ozempic, and their potential implications for gastrointestinal function. As these medications have gained widespread adoption for diabetes management and weight loss, a growing body of clinical observation has focused on reports of delayed gastric emptying, a condition known as gastroparesis. This transition from general health awareness to a targeted inquiry about drug exposure and its consequences is critical for understanding the evolving landscape of patient safety. The focus here is on the documented association between the use of these agents and the subsequent development of gastroparesis symptoms, which has led to legal and medical scrutiny. This pivot allows for a clearer examination of the criteria used to evaluate potential settlements for those affected, moving from broad health education to a precise, exposure-based risk assessment.

Understanding Gastroparesis and Ozempic

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can significantly impair quality of life and nutritional status. Ozempic (semaglutide) is a glucagon-like peptide 1 (GLP-1) receptor agonist approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Its mechanism involves slowing gastric emptying, which contributes to glycemic control but also underlies gastrointestinal adverse effects.

Clinical Evidence of Gastrointestinal Risks

Clinical trial data demonstrate that gastrointestinal adverse reactions occur more frequently among patients receiving Ozempic than placebo. In pooled placebo-controlled trials, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, 32.7% of those on Ozempic 0.5 mg, and 36.4% of those on Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently with the 2 mg dose (34.0%) versus 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% associated with Ozempic include dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal adverse events, consistent with the pharmacologic action of GLP-1 receptor agonists.

Mechanistic Link and Warning Adequacy

The mechanistic pathway linking Ozempic to gastroparesis involves delayed gastric emptying, a known effect of GLP-1 receptor agonists. While nausea and vomiting are common during dose escalation, persistent symptoms may indicate gastroparesis. The timeline between exposure and documented harm can vary; symptoms often emerge during the initial weeks of treatment or after dose increases. However, some patients may develop symptoms after prolonged use. The label does not explicitly list gastroparesis as an adverse reaction, but the reported gastrointestinal effects—including dyspepsia, gastroesophageal reflux disease, and gastritis—overlap with gastroparesis symptoms. Regarding the adequacy of warnings, the Ozempic label includes information about gastrointestinal adverse reactions but does not specifically warn about gastroparesis. This gap may be relevant for settlement considerations. Patients who developed gastroparesis after using Ozempic may argue that the warnings were insufficient to alert them to the risk of this serious condition.

Settlement Criteria and Considerations

Settlement criteria typically consider factors such as the severity of harm, the strength of the causal link, and the adequacy of product labeling. For affected patients, settlement-related considerations include documenting the timeline between Ozempic use and the onset of gastroparesis symptoms, obtaining a formal diagnosis through gastric emptying studies, and establishing that other causes of gastroparesis (e.g., diabetes, surgery, or idiopathic factors) have been ruled out. The presence of pre-existing diabetes complicates the analysis, as diabetic gastroparesis is a known complication. However, the temporal relationship and dose-response data may support a causal role for Ozempic. In summary, the evidence indicates that Ozempic is associated with a range of gastrointestinal adverse reactions, including those that could manifest as gastroparesis. The label provides data on these reactions but does not specifically warn about gastroparesis. Patients pursuing settlement claims should gather medical records documenting the exposure timeline, diagnosis, and exclusion of alternative causes. Legal evaluation of individual cases is necessary to determine eligibility based on the specific facts and applicable laws.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is gastroparesis and how is it diagnosed?

Gastroparesis is a disorder characterized by delayed gastric emptying without mechanical obstruction, causing symptoms like nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach.

How does Ozempic cause gastrointestinal side effects?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism for glycemic control. This slowing can lead to gastrointestinal adverse reactions such as nausea, vomiting, diarrhea, and potentially gastroparesis. Clinical trials show a dose-dependent increase in these effects (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What are the settlement criteria for Ozempic-related gastroparesis?

Settlement criteria typically consider the severity of harm, strength of the causal link, and adequacy of product labeling. Patients need to document the timeline of Ozempic use and symptom onset, obtain a formal gastroparesis diagnosis via gastric emptying studies, and rule out other causes such as diabetes or surgery. Legal evaluation is necessary for individual cases.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.